Long non-coding RNA (lncRNA) prostate cancer associated transcript 1 (PCAT-1) has been identified as a potential
biomarker for the diagnosis and prognosis of various cancers. We performed this systematic review and meta-analysis
to evaluate the role of dysregulation as well as the biological and clinical significance of lnc-PCAT-1 for predicting the
malignancy status in several cancers. Two independent reviewers conducted an extensive search in electronic databases
of Medline, Embase, Scopus, Web of Science and PubMed until the December of 2017. Five articles investigating the
clinical significance of lncRNA PCAT-1, including 996 patients, were analyzed. Our results revealed that the increased
PCAT-1 expression was related to overall survival (OS) (HR = 1.9, 95%CI: 1.13-3.18, P=0.015). Also, pooled results
of the diagnostic data analysis demonstrated that PCAT-1 has a sensitivity of 0.59 and specificity of 0.66 for cancer
diagnosis. Moreover, pooled area under curve was 0.62 (95% CI: 0.58–0.69). This meta-analysis revealed that lncRNA
PCAT-1 could be served as a potential diagnostic and prognostic biomarker in various solid tumors.
Biomarkers, Tumor Humans